Research has shown that carbon monoxide reduces the amount of damage caused to the organ due to lack of oxygen during the transfer process. Carbon monoxide in its gas form is unstable and difficult to work with, but the company has developed compounds that release carbon monoxide in a controlled manner. The molecules can be then infused into the organ to protect it from oxygen deprivation. This means the organs can survive longer outside the body. hemoCORM is currently investigating whether to treat the organ in the donor, during transfer, or once it is transferred to the recipient.
The Sheffield company is looking for funding in two stages, £800,000 and £2 million for preclinical trials and to investigate other applications for the compounds.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
